Document Classification

Section Type: RESULTS

Text: All-cause mortality was significantly reduced (1328 [12. 9 %] deaths among 10, 269 allocated simvastatin versus 1507 [14. 7 %] among 10, 267 allocated placebo ; p = 0. 0003), due to a highly significant 18 % (SE 5) proportional reduction in the coronary death rate (587 [5. 7 %] vs 707 [6. 9 %] ; p = 0. 0005), a marginally significant reduction in other vascular deaths (194 [1. 9 %] vs 230 [2. 2 %] ; p = 0. 07), and a non-significant reduction in non-vascular deaths (547 [5. 3 %] vs 570 [5. 6 %] ; p = 0. 4).